Systemic target therapeutic drugs, such as sorafenib, lenvatinib, or regorafenib are the only drugs that are known to be effective against advanced hepatocellular carcinoma (HCC). However, these agents show a limited efficacy in killing residual tumors. Immunotherapy is an alternative approach to this treatment and has been used to successfully treat different cancers, including HCC. HCC is an inflammation-induced cancer and represents a very interesting target for immunotherapeutics. Immunotherapies aim to reverse the immune tolerance and suppression found in tumor microenvironments and include approaches, such as adoptive cell therapy, immune checkpoint inhibition, and cancer vaccination. Adoptive cell therapy uses autologous natural killer or cytokine-induced killer cells by cultivating them ex vivo and subsequently reinfusing them into the patient. Immune checkpoint inhibitors reactivate tumorspecific T cells by suppressing checkpoint-mediated inhibitory signaling. Cancer vaccination induces a tumor-specific immune response by activating effector T lymphocytes. A wide range of potential immunotherapy-related adverse events occur; therefore, a multidisciplinary collaborative management is required across the clinical spectrum. This review summarizes the current status of immunotherapy for HCC and provides a perspective on its future applications.
IntroductIon
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths, with increasing incidences worldwide. 1 Although several attempts have been based approaches focusing on vaccination, treatment with cytokines, or non-specific T cell activation in HCC have mostly been unsuccessful. 11, 12 However, United States Food and Drag Administration (FDA) approval of immune checkpoint inhibitors brought about a dramatic change in the era of immuno-oncology. Nivolumab, which blocks programmed cell death protein-1 (PD-1) pathway, has been approved as a second-line therapeutic agent for advanced HCC, 13 and studies to evaluate its use as a first-line treatment for advanced HCC are ongoing.
Herein, we describe the mechanisms of immune interventions used for the treatment of HCC. We summarize data from recent studies, ongoing clinical trials, and adverse events resulting from immunotherapeutic use. In addition,
we discuss the development of immunotherapeutics that may be alternative treatment options for HCC in the future.
MechanIsMs of IMMune tolerance and suppressIon of hcc
The liver has a specific blood supply containing 25% he- growth factor-β. 15, 16 Infection with hepatitis B and C viruses leads to frequent chronic inflammation in the liver, resulting
in dysregulation of T cell responses. 17 Moreover, tumor growth favors this dysregulation, which is already present in HCC patients. 18 The ability of tumor cells to evade the immune system is a key for transformation of non-tumor cells into malignant cells. 19 The 
IndIrect IMMunologIcal strategIes
Immune checkpoint proteins include CTLA-4, PD-1, PD-L1, T cell immunoglobulin and mucin domain 3 (TIM-3), and lymphocyte activation gene 3 (LAG-3) (Fig. 3) . 30 Among these, inhibitors of CTLA-4 and PD-1 have been well-characterized in HCC (Table 1) .
Cancer vaccines induce tumor-specific immune responses by inducing effector T lymphocytes that can reduce tumor burden and prevent tumor recurrence. The agents used for HCC vaccines include HCC cells, antigens, DCs, and DNA. 
Immune Checkpoint Inhibitors

4) Biomarker for immune checkpoint inhibitors
To find the most suited patient population for immunotherapy, it is crucial to identify biomarkers to predict the re- response with a dense tumor-specific T-cell infiltrate is reported to occur in such patients. 41 Mizukoshi et al. 42 reported that TAA-specific T cells increase in 62.3% of patients after RFA, contributing to progression-free survival (PFS). Recently, Duffy et al. 32 performed a pilot study for the safety and feasibility of tremelimumab in combination with RFA or chemoablation. PFS rates were 57.1% at 6 months and 33.1% HCC. 44 In a phase II trial of an adjuvant GPC3 vaccine, patients received 10 vaccinations during the course of a year after surgery. The recurrence rate in patients who were vaccinated was significantly lower than that of the control patients (24% vs. 48%) after a one-year follow-up. A phase I/IIa study, using TAA (AFP, GPC3, and MAGE)-pulsed DCs for HCC patients after primary treatment, reported that DC vaccination was an effective adjuvant treatment. 48 The same group conducted a randomized phase II trial on 156 HCC patients who were treated for HCC with no evidence of residual tumors. 49 adverse events after IMMunotherapeutIc treatMent
Increasing immune system activation and blocking immune checkpoints may result in inflammatory side-effects.
Immunotherapy-related adverse events commonly involve the gastrointestinal tract, endocrine glands, skin, and liver (Fig. 4) . 56 
